SAN ANTONIO – Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant ...
ABSTRACT 2170O Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported ...
The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not ...
EMBARGOED TIPSHEET SABCS: Subgroup analysis of trastuzumab deruxtecan (T-DXd) shows ‘encouraging’ results in controlling stable brain metastases in HER2-positive metastatic ...
